SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0302 2838 OR L773:1873 7560 "

Sökning: L773:0302 2838 OR L773:1873 7560

  • Resultat 51-60 av 680
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
51.
  •  
52.
  • Bex, Axel, et al. (författare)
  • The Role of Cytoreductive Nephrectomy : European Association of Urology Recommendations in 2016
  • 2016
  • Ingår i: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 70:6, s. 901-905
  • Tidskriftsartikel (refereegranskat)abstract
    • Patient summary: After the introduction of systemic targeted therapies, the use of nephrectomy in patients with metastatic renal cell carcinoma has declined. Currently, systemic therapy is offered to more patients first as a means to select those candidates that will likely benefit from removal of their primary tumour. Although studies consistently demonstrate a survival benefit after nephrectomy, most patients with poor risk metastatic disease are unlikely to benefit from surgery. Soon studies will report on the effect of nephrectomy in patients with metastatic disease at diagnosis.
  •  
53.
  • Bex, Axel, et al. (författare)
  • Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
  • 2018
  • Ingår i: European Urology. - : Elsevier. - 0302-2838 .- 1873-7560. ; 74:6, s. 805-809
  • Tidskriftsartikel (refereegranskat)abstract
    • Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data.Patient summary: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered. 
  •  
54.
  • Bex, Axel, et al. (författare)
  • Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
  • 2017
  • Ingår i: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 71:5, s. 719-722
  • Tidskriftsartikel (refereegranskat)abstract
    • The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC). On the basis of conflicting results from the two available studies, the panel rated the quality of the evidence, the harm-to-benefit ratio, patient preferences, and costs. Finally, the panel, including representatives from a patient advocate group (International Kidney Cancer Coalition) voted and reached a consensus to not recommend adjuvant therapy with sunitinib for patients with high-risk RCC after nephrectomy. Patient summary: In two studies, sunitinib was given for 1 yr and compared to no active treatment (placebo) in patients who had their kidney tumour removed and who had a high risk of cancer coming back after surgery. Although one study demonstrated that 1 yr of sunitinib therapy resulted in a 1.2-yr longer time before the disease recurred, the other study did not show a benefit and it has not been shown that patients live longer. Despite having been diagnosed with high-risk disease, many patients remain without recurrence, and the side effects of sunitinib are high. Therefore, the panel members, including patient representatives, do not recommend sunitinib after tumour removal in these patients.
  •  
55.
  • Bill-Axelson, Anna, et al. (författare)
  • Long-term Distress After Radical Prostatectomy Versus Watchful Waiting in Prostate Cancer : A Longitudinal Study from the Scandinavian Prostate Cancer Group-4 Randomized Clinical Trial
  • 2013
  • Ingår i: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 64:6, s. 920-928
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:Studies enumerating the dynamics of physical and emotional symptoms following prostate cancer (PCa) treatment are needed to guide therapeutic strategy. Yet, overcoming patient selection forces is a formidable challenge for observational studies comparing treatment groups.OBJECTIVE:To compare patterns of symptom burden and distress in men with localized PCa randomized to radical prostatectomy (RP) or watchful waiting (WW) and followed up longitudinally.DESIGN, SETTING, AND PARTICIPANTS:The three largest, Swedish, randomization centers for the Scandinavian Prostate Cancer Group-4 trial conducted a longitudinal study to assess symptoms and distress from several psychological and physical domains by mailed questionnaire every 6 mo for 2 yr and then yearly through 8 yr of follow-up.INTERVENTION:RP compared with WW.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:A questionnaire was mailed at baseline and then repeatedly during follow-up with questions concerning physical and mental symptoms. Each analysis of quality of life was based on a dichotomization of the outcome (yes vs no) studied in a binomial response, generalized linear mixed model.RESULTS AND LIMITATIONS:Of 347 randomized men, 272 completed at least five questionnaires during an 8-yr follow-up period. Almost all men reported that PCa negatively influenced daily activities and relationships. Health-related distress, worry, feeling low, and insomnia were consistently reported by approximately 30-40% in both groups. Men in the RP group consistently reported more leakage, impaired erection and libido, and fewer obstructive voiding symptoms. For men in the WW group, distress related to erectile symptoms increased gradually over time. Symptom burden and distress at baseline was predictive of long-term outlook.CONCLUSIONS:Cancer negatively influenced daily activities among almost all men in both treatment groups; health-related distress was common. Trade-offs exist between physiologic symptoms, highlighting the importance of tailored treatment decision-making. Men who are likely to experience profound long-term distress can be identified early in disease management.
  •  
56.
  •  
57.
  •  
58.
  • Bjartell, Anders (författare)
  • "A Robot Saved My Life": Is It a Myth?
  • 2012
  • Ingår i: European Urology. - : Elsevier BV. - 1873-7560 .- 0302-2838. ; 62:5, s. 775-776
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
59.
  •  
60.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 51-60 av 680
Typ av publikation
tidskriftsartikel (585)
konferensbidrag (46)
forskningsöversikt (46)
annan publikation (2)
recension (1)
Typ av innehåll
refereegranskat (520)
övrigt vetenskapligt/konstnärligt (160)
Författare/redaktör
Bjartell, Anders (57)
Stattin, Pär (44)
Wiklund, P (44)
Lilja, Hans (37)
Liedberg, Fredrik (37)
Hugosson, Jonas, 195 ... (36)
visa fler...
Bex, Axel (30)
Gronberg, H (29)
Ljungberg, Börje (26)
Mottrie, A (24)
Marconi, Lorenzo (23)
Volpe, Alessandro (23)
Powles, Thomas (23)
Eklund, M (23)
Dabestani, Saeed (22)
Adolfsson, J. (22)
Stranne, Johan, 1970 (22)
Hofmann, Fabian (21)
Hora, Milan (21)
Hedlund, Petter (20)
Abrahamsson, Per-And ... (19)
Lam, Thomas B. (19)
Holmberg, Lars (18)
Egevad, L (18)
Gudjonsson, Sigurdur (18)
Steineck, Gunnar, 19 ... (18)
Tiselius, HG (17)
Giles, Rachel H. (17)
Aly, M (17)
Sjödahl, Gottfrid (16)
Carlsson, S (16)
Bratt, Ola (16)
Sooriakumaran, P (16)
Merseburger, Axel S. (15)
Bill-Axelson, Anna (15)
Roobol, Monique J (15)
Höglund, Mattias (15)
Andersson, Karl Erik (14)
Fernandez-Pello, Ser ... (14)
Albiges, Laurence (14)
Tahbaz, Rana (14)
Garmo, Hans (14)
Carlsson, Sigrid, 19 ... (14)
Malmström, Per-Uno (13)
Hosseini, A. (13)
Milsom, Ian, 1950 (13)
Montorsi, Francesco (13)
Kuczyk, Markus A. (13)
Staehler, Michael (13)
Bensalah, Karim (13)
visa färre...
Lärosäte
Karolinska Institutet (292)
Lunds universitet (259)
Göteborgs universitet (109)
Umeå universitet (102)
Uppsala universitet (82)
Linköpings universitet (37)
visa fler...
Örebro universitet (22)
Chalmers tekniska högskola (6)
Kungliga Tekniska Högskolan (2)
Stockholms universitet (1)
Gymnastik- och idrottshögskolan (1)
visa färre...
Språk
Engelska (680)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (427)
Naturvetenskap (3)
Lantbruksvetenskap (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy